Therapeutic Drug Monitoring Market By Product (Consumables, Equipment), By Technology (Immunoassays, Chromatography-Spectrometry, Others), By Drug Class (Antiepileptic Drugs, Antiarrhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Others), By End Users (Hospital, Diagnostic labs, Research and Academic Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2031

Therapeutic Drug Monitoring Market

Therapeutic drug monitoring (TDM) is the clinical monitoring of a drug's concentration in a patient's blood to optimize its therapeutic effect and minimize the risk of toxicity. It is used for drugs with a narrow therapeutic window and for drugs that may exhibit wide inter-patient variability in pharmacokineticsThe main objective of therapeutic drug monitoring is to maintain the concentration of drugs within a therapeutic range, which helps to improve patient outcomes, reduce adverse effects, and minimize healthcare costs. In this procedure, a sample of the patient’s blood is analyzed to monitor the concentration of the drug. 

The growth of the therapeutic drug monitoring market is driven by the growing prevalence of chronic diseases, increased awareness about therapeutic drug monitoring, and a rise in demand for therapeutic drug monitoring services in an emerging market. The rise in the prevalence of chronic diseases such as autoimmune disease, cardiovascular disease, and neurological disorders, among others across the world is the major factor that drives the growth of the market. As therapeutic drug monitoring (TDM) is an important tool that is used to measure the levels of drugs in a patient's blood to ensure appropriate therapeutic interventions and to reduce the risk of drug-related side effects. Furthermore, it helps doctors to adjust the medication dosages to ensure optimal treatment for individuals. It can also help doctors to detect the adverse reactions of medications and minimize the risk of drug interactions. For instance, according to World Health Organization (WHO) in 2022, it was estimated that around 50 million people worldwide are living with epilepsy and making it one of the most common neurological diseases globally. Furthermore, in high-income countries, it was estimated that about 49 per 100,000 patients are diagnosed with epilepsy each year. In low- and middle-income countries, this figure can be as high as 139 per 100,000. Furthermore, the rise in geriatric population across the world is the major factor that boosts the growth of the market as people in the geriatric population are more likely to have chronic conditions and require more frequent monitoring and adjustments to their medications. Thus, the increase in the prevalence of chronic diseases along with the rise in the geriatric population drives the growth of the market 

The market also offers growth opportunities to the key players in the market. The rise in advancements in therapeutic drug monitoring is the major factor expected to drive the growth of the market in the upcoming years. Technological advancements have enabled the development of automated therapeutic drug monitoring systems that can provide accurate and reliable results in a timely manner. For instance, automated systems can reduce the time and cost associated with manual testing and can be used to monitor patients in real-time. Furthermore, the development of advanced technologies such as automated liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology and automated clinical analyzers have enabled the rapid and reliable measurement of drug levels. These technologies have also enabled the development of sophisticated therapeutic drug monitoring algorithms that can accurately detect and measure drug levels, which can help clinicians to identify potential adverse effects and adjust treatment plans accordingly. Thus, these advances are facilitating the adoption of therapeutic drug monitoring across the world which further drives the growth of the market. 

The therapeutic drug monitoring market is segmented on the basis of product, technology, drug class, end user, and region. As per product, the market is classified into consumables and equipment. On the basis of technology, the market is segmented into immunoassay, chromatography-spectrometry, and others. According to the drug class, the market is divided into anti-epileptic drugs, antibiotics drugs, anti-arrhythmic drugs, immunosuppressants, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.  

The key players profiled in the study include Abbott Laboratories, Biomerieux SA, Bio-Rad Laboratories, Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, Exagen Inc, F. Hoffmann-La Roche Ltd., Sekisui Chemical Co Ltd., Siemens AG, and Thermo Fisher Scientific Inc. 

Key Market Insights 

By product, the consumable segment is expected to experience rapid growth in the market and is estimated to reach $ 2,820.08 million by 2031, with a CAGR of 9.1%. However, the equipment segment is estimated to be growing with a significant CAGR of 7.8% during the forecast period. 

By technology, the immunoassay segment dominated the global market. However, the chromatography-spectroscopy segment is expected to grow with a significant CAGR of 8.7% during the forecast period. 

By end user, the hospitals segment dominated the global market. However, the diagnostic segment is expected to grow with a significant CAGR of 8.6% during the forecast period 

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 9.5% during the forecast period 

 

Overview

The global therapeutic drug monitoring market was valued at $1,932.93 million in 2021 and is projected to reach $4,415.3 million by 2031, registering a CAGR of 8.5% from 2022 to 2031. Therapeutic drug monitoring (TDM) is a clinical practice in which the concentration of a specific drug in a patient's blood is measured to optimize dosage regimens, and treatment, and minimize toxicity. Therapeutic drug monitoring is used to account for individual variability in drug metabolism, minimize the risk of toxicity, identify and manage drug interactions, and improve the safety and efficacy of drug treatment. It is a valuable tool in the management of drug treatment, offering numerous advantages in terms of safety, efficacy, and personalized care. Therapeutic drug concentration is monitored through immunoassays, calorimetric immunoassays, and chromatography-mass spectrometry.

The therapeutic drug monitoring market growth is driven by the growing prevalence of chronic diseases, an increase in awareness about therapeutic drug monitoring, and a rise in demand for therapeutic drug monitoring services in emerging markets. The rise in the prevalence of chronic diseases such as cardiovascular diseases, cancer, and neurodegenerative diseases, which require long-term treatment with drugs that have a narrow therapeutic window, is driving the demand for therapeutic drug monitoring services. For instance, according to International Diabetes Federation, in 2021, it was estimated that about 537 million adults (20-79 years) are living with diabetes in the world and is expected to reach 643 million by 2030. Thus, an increase in the prevalence of chronic diseases and the need for long-term treatment is expected to boost the demand for therapeutic drug monitoring services, which, in turn, contribute toward market growth. Furthermore, the increasing demand for advanced and innovative consumables such as immunoassays is the key factor contributing to the growth of the market. For instance, Eagle Biosciences offers various therapeutic drug monitoring assays such as Alemtuzumab ELISA Assay which is used for the quantitative determination of Alemtuzumab (Lemrada) drug in in the patient’s blood. However, a lack of skilled professionals present in the market, and technical errors in sample collection can limit the adoption of therapeutic drug monitoring products, which, in turn, hinders the growth of the market in upcoming years. On the other hand, increased focus on R&D activities for therapeutic drug monitoring and growth potential in emerging markets are expected to create immense opportunities for therapeutic drug monitoring during the forecast period.

The therapeutic drug monitoring market is segmented on the basis of product, technology, drug class, end user and region. As per product, the market is classified into consumables and equipment. On the basis of technology, the market is segmented into immunoassay, chromatography-spectrometry, and others. According to the drug class, the market is divided into anti-epileptic drugs, antibiotics drugs, anti-arrhythmic drugs, immunosuppressants, and others.

Depending on end-user, the market is classified into hospitals, diagnostic lab, and research and academic institutes. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the global therapeutic drug monitoring market are Abbott Laboratories, Biomerieux SA, Bio-Rad Laboratories, Inc., Chromsystems Instruments & Chemicals GmbH, Danaher Corporation, Exagen Inc, F. Hoffmann-La Roche Ltd., Sekisui Chemical Co Ltd., Siemens AG, and Thermo Fisher Scientific Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the therapeutic drug monitoring market analysis from 2021 to 2031 to identify the prevailing therapeutic drug monitoring market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the therapeutic drug monitoring market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global therapeutic drug monitoring market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Exagen Inc

Scope of Therapeutic Drug Monitoring Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in the prevalence of chronic disease.

3.4.1.2. Rise in the adoption of precision medicine

3.4.1.3. Rise in technological advancement

3.4.2. Restraints

3.4.2.1. Lack of skilled professionals

3.4.3. Opportunities

3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Consumables

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Equipment

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Immunoassays

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Chromatography-Spectrometry

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Antiepileptic Drugs

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Antiarrhythmic Drugs

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Immunosuppressant Drugs

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

6.5. Antibiotic Drugs

6.5.1. Key market trends, growth factors and opportunities

6.5.2. Market size and forecast, by region

6.5.3. Market share analysis by country

6.6. Others

6.6.1. Key market trends, growth factors and opportunities

6.6.2. Market size and forecast, by region

6.6.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast

7.2. Hospital

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Diagnostic labs

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Research and Academic Institutes

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America

8.2.1. Key trends and opportunities

8.2.2. Market size and forecast, by Product

8.2.3. Market size and forecast, by Technology

8.2.4. Market size and forecast, by Drug Class

8.2.5. Market size and forecast, by End Users

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Key market trends, growth factors and opportunities

8.2.6.1.2. Market size and forecast, by Product

8.2.6.1.3. Market size and forecast, by Technology

8.2.6.1.4. Market size and forecast, by Drug Class

8.2.6.1.5. Market size and forecast, by End Users

8.2.6.2. Canada

8.2.6.2.1. Key market trends, growth factors and opportunities

8.2.6.2.2. Market size and forecast, by Product

8.2.6.2.3. Market size and forecast, by Technology

8.2.6.2.4. Market size and forecast, by Drug Class

8.2.6.2.5. Market size and forecast, by End Users

8.2.6.3. Mexico

8.2.6.3.1. Key market trends, growth factors and opportunities

8.2.6.3.2. Market size and forecast, by Product

8.2.6.3.3. Market size and forecast, by Technology

8.2.6.3.4. Market size and forecast, by Drug Class

8.2.6.3.5. Market size and forecast, by End Users

8.3. Europe

8.3.1. Key trends and opportunities

8.3.2. Market size and forecast, by Product

8.3.3. Market size and forecast, by Technology

8.3.4. Market size and forecast, by Drug Class

8.3.5. Market size and forecast, by End Users

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Key market trends, growth factors and opportunities

8.3.6.1.2. Market size and forecast, by Product

8.3.6.1.3. Market size and forecast, by Technology

8.3.6.1.4. Market size and forecast, by Drug Class

8.3.6.1.5. Market size and forecast, by End Users

8.3.6.2. France

8.3.6.2.1. Key market trends, growth factors and opportunities

8.3.6.2.2. Market size and forecast, by Product

8.3.6.2.3. Market size and forecast, by Technology

8.3.6.2.4. Market size and forecast, by Drug Class

8.3.6.2.5. Market size and forecast, by End Users

8.3.6.3. UK

8.3.6.3.1. Key market trends, growth factors and opportunities

8.3.6.3.2. Market size and forecast, by Product

8.3.6.3.3. Market size and forecast, by Technology

8.3.6.3.4. Market size and forecast, by Drug Class

8.3.6.3.5. Market size and forecast, by End Users

8.3.6.4. Italy

8.3.6.4.1. Key market trends, growth factors and opportunities

8.3.6.4.2. Market size and forecast, by Product

8.3.6.4.3. Market size and forecast, by Technology

8.3.6.4.4. Market size and forecast, by Drug Class

8.3.6.4.5. Market size and forecast, by End Users

8.3.6.5. Spain

8.3.6.5.1. Key market trends, growth factors and opportunities

8.3.6.5.2. Market size and forecast, by Product

8.3.6.5.3. Market size and forecast, by Technology

8.3.6.5.4. Market size and forecast, by Drug Class

8.3.6.5.5. Market size and forecast, by End Users

8.3.6.6. Rest of Europe

8.3.6.6.1. Key market trends, growth factors and opportunities

8.3.6.6.2. Market size and forecast, by Product

8.3.6.6.3. Market size and forecast, by Technology

8.3.6.6.4. Market size and forecast, by Drug Class

8.3.6.6.5. Market size and forecast, by End Users

8.4. Asia-Pacific

8.4.1. Key trends and opportunities

8.4.2. Market size and forecast, by Product

8.4.3. Market size and forecast, by Technology

8.4.4. Market size and forecast, by Drug Class

8.4.5. Market size and forecast, by End Users

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Key market trends, growth factors and opportunities

8.4.6.1.2. Market size and forecast, by Product

8.4.6.1.3. Market size and forecast, by Technology

8.4.6.1.4. Market size and forecast, by Drug Class

8.4.6.1.5. Market size and forecast, by End Users

8.4.6.2. China

8.4.6.2.1. Key market trends, growth factors and opportunities

8.4.6.2.2. Market size and forecast, by Product

8.4.6.2.3. Market size and forecast, by Technology

8.4.6.2.4. Market size and forecast, by Drug Class

8.4.6.2.5. Market size and forecast, by End Users

8.4.6.3. Australia

8.4.6.3.1. Key market trends, growth factors and opportunities

8.4.6.3.2. Market size and forecast, by Product

8.4.6.3.3. Market size and forecast, by Technology

8.4.6.3.4. Market size and forecast, by Drug Class

8.4.6.3.5. Market size and forecast, by End Users

8.4.6.4. India

8.4.6.4.1. Key market trends, growth factors and opportunities

8.4.6.4.2. Market size and forecast, by Product

8.4.6.4.3. Market size and forecast, by Technology

8.4.6.4.4. Market size and forecast, by Drug Class

8.4.6.4.5. Market size and forecast, by End Users

8.4.6.5. South Korea

8.4.6.5.1. Key market trends, growth factors and opportunities

8.4.6.5.2. Market size and forecast, by Product

8.4.6.5.3. Market size and forecast, by Technology

8.4.6.5.4. Market size and forecast, by Drug Class

8.4.6.5.5. Market size and forecast, by End Users

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Key market trends, growth factors and opportunities

8.4.6.6.2. Market size and forecast, by Product

8.4.6.6.3. Market size and forecast, by Technology

8.4.6.6.4. Market size and forecast, by Drug Class

8.4.6.6.5. Market size and forecast, by End Users

8.5. LAMEA

8.5.1. Key trends and opportunities

8.5.2. Market size and forecast, by Product

8.5.3. Market size and forecast, by Technology

8.5.4. Market size and forecast, by Drug Class

8.5.5. Market size and forecast, by End Users

8.5.6. Market size and forecast, by country

8.5.6.1. Brazil

8.5.6.1.1. Key market trends, growth factors and opportunities

8.5.6.1.2. Market size and forecast, by Product

8.5.6.1.3. Market size and forecast, by Technology

8.5.6.1.4. Market size and forecast, by Drug Class

8.5.6.1.5. Market size and forecast, by End Users

8.5.6.2. Saudi Arabia

8.5.6.2.1. Key market trends, growth factors and opportunities

8.5.6.2.2. Market size and forecast, by Product

8.5.6.2.3. Market size and forecast, by Technology

8.5.6.2.4. Market size and forecast, by Drug Class

8.5.6.2.5. Market size and forecast, by End Users

8.5.6.3. South Africa

8.5.6.3.1. Key market trends, growth factors and opportunities

8.5.6.3.2. Market size and forecast, by Product

8.5.6.3.3. Market size and forecast, by Technology

8.5.6.3.4. Market size and forecast, by Drug Class

8.5.6.3.5. Market size and forecast, by End Users

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Key market trends, growth factors and opportunities

8.5.6.4.2. Market size and forecast, by Product

8.5.6.4.3. Market size and forecast, by Technology

8.5.6.4.4. Market size and forecast, by Drug Class

8.5.6.4.5. Market size and forecast, by End Users

9.1. Introduction

9.2. Top winning strategies

9.3. Product Mapping of Top 10 Player

9.4. Competitive Dashboard

9.5. Competitive Heatmap

9.6. Top player positioning, 2021

10.1. Bio-Rad Laboratories, Inc.

10.1.1. Company overview

10.1.2. Key Executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Business performance

10.1.7. Key strategic moves and developments

10.2. Siemens AG

10.2.1. Company overview

10.2.2. Key Executives

10.2.3. Company snapshot

10.2.4. Operating business segments

10.2.5. Product portfolio

10.2.6. Business performance

10.3. F. Hoffmann-La Roche Ltd.

10.3.1. Company overview

10.3.2. Key Executives

10.3.3. Company snapshot

10.3.4. Operating business segments

10.3.5. Product portfolio

10.3.6. Business performance

10.4. Abbott Laboratories

10.4.1. Company overview

10.4.2. Key Executives

10.4.3. Company snapshot

10.4.4. Operating business segments

10.4.5. Product portfolio

10.4.6. Business performance

10.5. Biomerieux SA

10.5.1. Company overview

10.5.2. Key Executives

10.5.3. Company snapshot

10.5.4. Operating business segments

10.5.5. Product portfolio

10.5.6. Business performance

10.6. Danaher Corporation

10.6.1. Company overview

10.6.2. Key Executives

10.6.3. Company snapshot

10.6.4. Operating business segments

10.6.5. Product portfolio

10.6.6. Business performance

10.7. Exagen Inc.

10.7.1. Company overview

10.7.2. Key Executives

10.7.3. Company snapshot

10.7.4. Operating business segments

10.7.5. Product portfolio

10.7.6. Business performance

10.8. Thermo Fisher Scientific Inc.

10.8.1. Company overview

10.8.2. Key Executives

10.8.3. Company snapshot

10.8.4. Operating business segments

10.8.5. Product portfolio

10.8.6. Business performance

10.9. SEKISUI CHEMICAL CO., LTD.

10.9.1. Company overview

10.9.2. Key Executives

10.9.3. Company snapshot

10.9.4. Operating business segments

10.9.5. Product portfolio

10.9.6. Business performance

10.10. Chromsystems Instruments & Chemicals GmbH

10.10.1. Company overview

10.10.2. Key Executives

10.10.3. Company snapshot

10.10.4. Operating business segments

10.10.5. Product portfoli

LIST OF TABLES

TABLE 01. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 02. THERAPEUTIC DRUG MONITORING MARKET FOR CONSUMABLES, BY REGION, 2021-2031 ($MILLION)

TABLE 03. THERAPEUTIC DRUG MONITORING MARKET FOR EQUIPMENT, BY REGION, 2021-2031 ($MILLION)

TABLE 04. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 05. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2021-2031 ($MILLION)

TABLE 06. THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-SPECTROMETRY, BY REGION, 2021-2031 ($MILLION)

TABLE 07. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 08. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 09. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY REGION, 2021-2031 ($MILLION)

TABLE 10. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY REGION, 2021-2031 ($MILLION)

TABLE 11. THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2021-2031 ($MILLION)

TABLE 12. THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2021-2031 ($MILLION)

TABLE 13. THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 15. THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL, BY REGION, 2021-2031 ($MILLION)

TABLE 16. THERAPEUTIC DRUG MONITORING MARKET FOR DIAGNOSTIC LABS, BY REGION, 2021-2031 ($MILLION)

TABLE 17. THERAPEUTIC DRUG MONITORING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2021-2031 ($MILLION)

TABLE 18. THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 19. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 20. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 21. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 22. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 23. NORTH AMERICA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 24. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 25. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 26. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 27. U.S. THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 28. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 29. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 30. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 31. CANADA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 32. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 33. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 34. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 35. MEXICO THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 36. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 37. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 38. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 39. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 40. EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 41. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 42. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 43. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 44. GERMANY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 45. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 46. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 47. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 48. FRANCE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 49. UK THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 50. UK THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 51. UK THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 52. UK THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 53. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 54. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 55. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 56. ITALY THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 57. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 58. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 59. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 60. SPAIN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 61. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 62. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 63. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 64. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 65. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 66. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 67. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 68. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 69. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 70. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 71. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 72. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 73. JAPAN THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 74. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 75. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 76. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 77. CHINA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 78. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 79. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 80. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 81. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 82. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 83. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 84. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 85. INDIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 86. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 87. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 88. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 89. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 90. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 91. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 92. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 93. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 94. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 95. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 96. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 97. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 98. LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 99. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 100. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 101. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 102. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 103. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 104. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 105. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 106. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 107. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 108. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 109. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 110. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 111. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021-2031 ($MILLION)

TABLE 112. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)

TABLE 113. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)

TABLE 114. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021-2031 ($MILLION)

TABLE 115. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES

TABLE 116. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 117. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS

TABLE 118. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 119. BIO-RAD LABORATORIES, INC.: KEY STRATERGIES

TABLE 120. SIEMENS AG: KEY EXECUTIVES

TABLE 121. SIEMENS AG: COMPANY SNAPSHOT

TABLE 122. SIEMENS AG: PRODUCT SEGMENTS

TABLE 123. SIEMENS AG: PRODUCT PORTFOLIO

TABLE 124. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 125. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 128. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 129. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 130. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 131. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 132. BIOMERIEUX SA: KEY EXECUTIVES

TABLE 133. BIOMERIEUX SA: COMPANY SNAPSHOT

TABLE 134. BIOMERIEUX SA: PRODUCT SEGMENTS

TABLE 135. BIOMERIEUX SA: PRODUCT PORTFOLIO

TABLE 136. DANAHER CORPORATION: KEY EXECUTIVES

TABLE 137. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 138. DANAHER CORPORATION: PRODUCT SEGMENTS

TABLE 139. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 140. EXAGEN INC.: KEY EXECUTIVES

TABLE 141. EXAGEN INC.: COMPANY SNAPSHOT

TABLE 142. EXAGEN INC.: PRODUCT SEGMENTS

TABLE 143. EXAGEN INC.: PRODUCT PORTFOLIO

TABLE 144. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES

TABLE 145. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 146. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS

TABLE 147. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 148. SEKISUI CHEMICAL CO., LTD.: KEY EXECUTIVES

TABLE 149. SEKISUI CHEMICAL CO., LTD.: COMPANY SNAPSHOT

TABLE 150. SEKISUI CHEMICAL CO., LTD.: PRODUCT SEGMENTS

TABLE 151. SEKISUI CHEMICAL CO., LTD.: PRODUCT PORTFOLIO

TABLE 152. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: KEY EXECUTIVES

TABLE 153. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY SNAPSHOT

TABLE 154. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT SEGMENTS

TABLE 155. CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. THERAPEUTIC DRUG MONITORING MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF THERAPEUTIC DRUG MONITORING MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN THERAPEUTIC DRUG MONITORING MARKET (2022-2031)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW BARGAINING POWER OF BUYERS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW THREAT OF NEW ENTRANTS

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALTHERAPEUTIC DRUG MONITORING MARKET

FIGURE 10. THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR CONSUMABLES, BY COUNTRY 2021-2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR EQUIPMENT, BY COUNTRY 2021-2031(%)

FIGURE 13. THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY 2021-2031(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-SPECTROMETRY, BY COUNTRY 2021-2031(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)

FIGURE 17. THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2021(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY 2021-2031(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY 2021-2031(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY 2021-2031(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY 2021-2031(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)

FIGURE 23. THERAPEUTIC DRUG MONITORING MARKET, BY END USERS, 2021(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL, BY COUNTRY 2021-2031(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR DIAGNOSTIC LABS, BY COUNTRY 2021-2031(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC DRUG MONITORING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY 2021-2031(%)

FIGURE 27. THERAPEUTIC DRUG MONITORING MARKET BY REGION, 2021

FIGURE 28. U.S. THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 29. CANADA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 30. MEXICO THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 31. GERMANY THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 32. FRANCE THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 33. UK THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 34. ITALY THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 35. SPAIN THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 36. REST OF EUROPE THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 37. JAPAN THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 38. CHINA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 39. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 40. INDIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 41. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 42. REST OF ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 43. BRAZIL THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 44. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 45. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 46. REST OF LAMEA THERAPEUTIC DRUG MONITORING MARKET, 2021-2031 ($MILLION)

FIGURE 47. TOP WINNING STRATEGIES, BY YEAR

FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 51. COMPETITIVE DASHBOARD

FIGURE 52. COMPETITIVE HEATMAP: THERAPEUTIC DRUG MONITORING MARKET

FIGURE 53. TOP PLAYER POSITIONING, 2021

FIGURE 54. BIO-RAD LABORATORIES, INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 55. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 56. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 57. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 58. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 59. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 61. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)

FIGURE 64. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 65. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 66. BIOMERIEUX SA: NET SALES, 2019-2021 ($MILLION)

FIGURE 67. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 68. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 69. DANAHER CORPORATION: NET SALES, 2019-2021 ($MILLION)

FIGURE 70. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 71. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 72. EXAGEN INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 73. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 74. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 75. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 76. SEKISUI CHEMICAL CO., LTD.: NET SALES, 2019-2021 ($MILLION)

FIGURE 77. SEKISUI CHEMICAL CO., LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 78. SEKISUI CHEMICAL CO., LTD.: REVENUE SHARE BY REGION, 2021 (%